Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 26, 2023

Utility of CRP as a Prognostic Biomarker to Guide Lenzilumab Treatment in Patients With COVID-19



Additional Info

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial
Thorax 2023 Jun 01;78(6)606-616, Z Temesgen, CF Kelley, F Cerasoli, A Kilcoyne, D Chappell, C Durrant, O Ahmed, G Chappell, V Catterson, C Polk, A Badley, VC Marconi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading